Correction to: British Journal of Cancer (2016) 114, 723–730. doi:10.1038/bjc.2016.41; published online 22 March 2016
Updated online 26 May 2016: This article was originally published under a standard BJC licence, but has now been made available under a CC BY 4.0 licence. The PDF and HTML versions of the paper have been modified accordingly.
Additional information
The online version of the original article can be found at 10.1038/bjc.2016.41
Rights and permissions
This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Drew, Y., Ledermann, J., Hall, G. et al. Erratum: Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer 114, e21 (2016). https://doi.org/10.1038/bjc.2016.133
Published:
Issue Date:
DOI: https://doi.org/10.1038/bjc.2016.133
This article is cited by
-
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Molecular Cancer (2023)
-
Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer
npj Breast Cancer (2022)
-
Emerging Therapies in the Management of High-Grade Serous Ovarian Carcinoma: a Focus on PARP Inhibitors
Current Obstetrics and Gynecology Reports (2017)
